Pay in 4 interest-free payments of $6.76 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Remember, open communication with your healthcare provider is key to ensuring your treatment is both effective and comfortable
The triple therapy of metformin, a DPP-4 inhibitor and a SGLT-2 inhibitor has a very low treatment related hypoglycaemia risk, leads to a further, almost additive reduction of glycaemic parameters, a body weight loss in the same range as with a mono- or dual therapy with a SGLT-2 inhibitor and also to the expected SGLT-2 inhibitor induced reduction of blood pressure
To this end, we often prescribe GLP-1 agonists, specifically Semaglutide GLP-1 and Liraglutide, due to their efficacy in reducing blood glucose levels and promoting weight loss
Ferreira JP, Saraiva F, Sharma A, Vasques-Nvoa F, AnglicoGonalves A, Leite AR, et al
